TCRX Q4 2024 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$665,000-90.8% YoY

Gross Profit

$665,000100.0% margin

Operating Income

-$37M-5520.6% margin

Net Income

-$36M-5384.8% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

-36.6%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$28M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$371M

Total Liabilities

$130M

Stockholders' Equity

$241M

Cash & Equivalents

$179M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$665,000	$7M	-90.8%
Gross Profit	$665,000	$6M	-88.8%
Operating Income	-$37M	-$21M	-71.9%
Net Income	-$36M	-$20M	-82.6%